MoonLake Immunotherapeutics Class A Ordinary Shares MLTX

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

• GlobeNewswire Inc. 21 sept

  Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

  The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.

  

• The Motley Fool 3 jul

  MoonLake Immunotherapeutics' CFO Sells 39K Shares

  MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 39,120 shares worth approximately $862,000 on June 22 through a pre-planned 10b5-1 trading plan. The sale represented 3.4% of his direct holdings, leaving him with over 1.1 million shares. While the transaction shouldn't concern investors due to its pre-planned nature, the clinical-stage biotech company remains highly volatile with no approved products or revenue.

  

• GlobeNewswire Inc. 23 jun

  MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

  MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotech company, announced the pricing of an underwritten public offering of 9 million Class A ordinary shares at $20.00 per share and 1 million pre-funded warrants, expected to raise approximately $200 million in gross proceeds. The company plans to use the net proceeds to fund research, development, and commercialization activities for sonelokimab, its investigational treatment for inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis. The offering is expected to close on or about June 25, 2026.